# Aptar account plan

> Aptar is a NYSE-listed maker of drug and consumer dispensing, dosing and protection systems with $3.78 billion 2025 sales and about 14,000 employees.

## At a glance

AptarGroup, Inc. (NYSE: ATR), headquartered in Crystal Lake, Illinois, designs and manufactures dispensing pumps, closures, aerosol valves, elastomeric components for injectables, active material science solutions and digital health solutions. It serves pharmaceutical, fragrance, skincare, cosmetics, food, beverage, personal care and home care customers, approximately 5,000 in all, with Europe at 49% of sales. FY2025 net sales rose 5% to $3.78 billion, with net income attributable to Aptar of $392.8 million and an Adjusted EBITDA margin of 21.6%. It has approximately 14,000 employees in approximately 20 countries.

## Business units

- **Pharma** (approximately 46% of 2025 Net Sales ($1.74 billion)): Nasal spray pumps, metered dose inhaler valves, elastomer components for injectables (including GLP-1 and biologics), active material science and digital health. Q3 2026 sales were $454.0 million (core +1%, or 8% adjusting for emergency medicine destocking) at a 36.4% Adjusted EBITDA margin. Gael Touya led it until becoming CEO; Virginie Maes becomes President of Aptar Pharma on January 1.
- **Beauty** (35% of 2025 Net Sales ($1.31 billion)): Pumps, airless systems and valves for fragrance, color cosmetics, facial skincare, personal care and home care. Q3 2026 sales rose 9% to $357.4 million, but the margin fell to 11.4% on mix and ongoing challenges in North American operations. Led by Marc Prieur.
- **Closures** (19% of 2025 Net Sales ($730.3 million)): Dispensing and non-dispensing closures for food, beverage, personal care and home care, plus food protection and elastomeric flow-control. Q3 2026 sales rose 11% to $207.8 million with beverage +19%, at a 15.5% margin diluted by input-cost pass-throughs. Led by Hedi Tlili.

## Strategic priorities

- **Profitable growth over sales growth**: The new CEO's priorities are profitable growth, execution and disciplined capital allocation, converting demand into more consistent profitability.
- **Pharma pipeline**: Reaffirmed long-term Pharma core growth corridor of 7% to 11%, built on ophthalmic, nasal, inhalation and injectables programmes such as Beat the Blink with Bausch + Lomb, the PULMOTREE Kolibri liquid inhaler and the Premia Precision injectables standard.
- **Beauty North America turnaround**: A diagnostic of North American Beauty is nearly complete; management describes a transformation of how it competes and executes that will take time.
- **Cost and ROIC management**: Managing fixed costs and improving return on invested capital through Global Business Service Centers, among five strategic focus areas in the 10-K.
- **Sustainable packaging**: SBTi-validated Scope 1, 2 and 3 targets, recyclable product lines, and low-carbon pMDI propellant work following the HFC phase-down.

## Latest results

In Q3 2026 net sales rose 6% to $1.02 billion with core sales up 5% across all three segments. Adjusted EPS was $1.52, at the higher end of guidance, and the Adjusted EBITDA margin was 21.3% against 23.2%. Reported net income fell to $32.6 million after a $58.0 million loss on deconsolidating the Russian subsidiary. Over nine months sales were $3.03 billion (+8%) and adjusted EPS $4.13 (-10%), with emergency medicine sales expected down about $65 million in 2026. Q4 2026 adjusted EPS guidance is $1.39 to $1.47.

## Investments and deals

- **Capital investments**: Capex of $270.4 million in 2025 and expected at $260 million to $280 million in 2026, including Pharma expansion in Mumbai.
- **Acquisitions**: Sommaplast for $27.0 million (December 2025), BTY raised to 80% for approximately $29.0 million (July 2025), 40% of Goldrain for approximately $99.0 million (October 2024), and PULMOTREE.
- **Shareholder returns**: $485.8 million returned in 2025, a new $600.0 million buyback authorization in February 2026, and the quarterly dividend raised from $0.48 to $0.50.
- **Financing**: $600.0 million of 4.75% Senior Notes due March 2031 issued in November 2025.

## Challenges and risks

- **Emergency medicine decline**: Naloxone (emergency medicine) sales fall about $65 million in 2026 as the product shifts to OTC and generics.
- **North American Beauty**: Beauty margins fell on unfavourable mix and ongoing challenges in North American operations, where Aptar is subscale in indie brands and lost share with certain customers.
- **Russia deconsolidation**: OOO Aptar Vladimir was placed under external administration on September 21, 2026, costing $61.2 million before tax including $30.0 million of inaccessible cash.
- **Input costs and pass-throughs**: Middle East-related input costs and pass-throughs with no margin diluted Closures and Beauty margins in 2026.
- **Regulation and litigation**: PFAS bans, EU PPWR and California packaging law, and litigation with ARS Pharmaceuticals and Nemera.

## What leadership says

> "Sales growth alone is not our objective. Our goal is to convert the strong demand for our products into more consistent profitability." — Gael Touya, President and Chief Executive Officer, Q3 2026 earnings call, October 30, 2026

> "I'm not satisfied with the performance of North America." — Gael Touya, President and Chief Executive Officer, Q3 2026 earnings call, October 30, 2026, on Beauty

> "We are not predicated on any one drug." — Gael Touya, President and Chief Executive Officer, Q3 2026 earnings call, October 30, 2026

> "Aptar is entering its next chapter from a position of strength." — Stephan Tanda, President and Chief Executive Officer, Q2 2026 earnings call, July 31, 2026, his final call as CEO


## Where a supplier can help

- **Operational excellence in Beauty**: The North American Beauty transformation targets planning, efficiency, quality and supply chain, opening room for operations consulting, planning software and quality systems.
- **Injectables quality and automation**: The Pharma pipeline priority, with Premia Precision's 100% automated vision inspection and Mumbai expansion, favours clean-room, inspection and automation suppliers.
- **Input-cost management**: Input costs passed through with no margin point to value for procurement analytics, resin sourcing and indexation management.
- **Sustainable materials**: PPWR and PFAS regulation and the sustainable packaging priority suggest demand for recycled resins, mono-material design and lifecycle assessment.
- **Shared services and ROIC**: The focus on fixed costs through Global Business Service Centers fits finance, HR and IT shared-services providers.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [AptarGroup, Inc. Form 10-K for fiscal year 2025](https://www.sec.gov/Archives/edgar/data/896622/000089662226000007/atr-20251231.htm)

Annual report · 2026-02-06

- Aptar (AptarGroup, Inc., NYSE: ATR) designs and manufactures drug and consumer product dosing, dispensing and protection technologies: dispensing pumps, closures, aerosol valves, elastomeric primary packaging components, active material science solutions and digital health solutions. HQ Crystal Lake, Illinois; approximately 14,000 employees in approximately 20 countries; approximately 5,000 customers, none above 4% of 2025 Net Sales.
- FY2025: reported net sales increased 5% to $3.78 billion, core sales increased 2%; net income attributable to Aptar $392.8 million; reported EPS $5.89 (adjusted $5.74); Adjusted EBITDA margin 21.6%; operating income $501.0 million (13.3% of sales).
- Three segments: Pharma (approximately 46% of Net Sales, 69% of Adjusted EBITDA excluding corporate costs, 35.0% Adjusted EBITDA margin), Beauty (35% of sales, 18% of Adjusted EBITDA, 12.1% margin), Closures (19% of sales, 13% of Adjusted EBITDA, 16.0% margin).
- Growth drivers in 2025: injectables core sales +11% on GLP-1 component sales, prescription drug +5% (emergency medicine, central nervous system, royalties), Beauty personal care +13%, Closures beverage +6%; weak spots were consumer health care (-8%), F&F (-4%) and North American indie skincare.
- Europe is the largest region at 49% of sales (shipped-to basis); Asia and Latin America together 20%; about 8,640 of the 14,000 employees are in EMEA.
- Capital allocation: capex $270.4 million (about 7% of sales), 2026 capital investments expected at $260.0-$280.0 million; $485.8 million returned to shareholders; 32nd consecutive year of increasing dividend; new $600.0 million buyback authorization (February 3, 2026); $600.0 million 4.75% notes issued; net debt to net capital 28.6%.
- M&A: Sommaplast acquired (December 2025, $27.0 million), BTY stake raised to 80% (July 2025, approximately $29.0 million), 40% of Goldrain (October 2024, approximately $99.0 million).
- Risks: tariffs and geopolitics (Russia sanctions), single-source resins and rubber for Pharma, raw material costs, PPWR/PFAS and plastics regulation, litigation with ARS Pharmaceuticals and Nemera, about $1.08 billion of goodwill.
- Executive team at February 6, 2026: Stephan Tanda (President and CEO since February 2017), Vanessa Kanu (CFO since January 2025), segment presidents Gael Touya (Pharma), Marc Prieur (Beauty), Hedi Tlili (Closures).

### [AptarGroup, Inc. Form 10-Q for the quarter ended September 30, 2026](https://www.sec.gov/Archives/edgar/data/896622/000089662226000190/atr-20260930.htm)

Interim report · 2026-10-30

- Q3 2026 (quarter to September 30, 2026): net sales $1.02 billion, up 6% from $961.1 million; core sales +5%. Nine months: net sales $3.03 billion (+8%), core +2%.
- Operating income $135.0 million (13.3% of sales vs 14.3%); net income attributable to Aptar $32.6 million in Q3 vs $127.9 million, hit by the Russia deconsolidation.
- On September 21, 2026 a Russian presidential decree placed OOO Aptar Vladimir under external administration; Aptar deconsolidated it and recorded a $58.0 million loss (including $18.7 million of cumulative translation adjustments and $30.0 million of inaccessible cash), plus a $2.6 million CECL reserve and $0.5 million of legal costs.
- Pharma Q3 sales $454.0 million (+2%, core +1%); prescription drug core -7% on the anticipated emergency medicine decline; consumer health care +13%; injectables +9% (GLP-1, biologics, vaccines); Adjusted EBITDA margin 36.4% (37.2%).
- Beauty Q3 sales $357.4 million (+9%, core +8%); prestige fragrance, color cosmetics and hair care; margin 11.4% (12.1%) on mix and "ongoing challenges in our North American operations".
- Closures Q3 sales $207.8 million (+11%, core +11%); beverage +19% (concentrates, bottled water), food +9%; margin 15.5% (16.1%) as input costs are passed through with no margin.
- Balance sheet: interest-bearing debt $1.38 billion; net debt to net capital 30.6%; nine-month capex $192.0 million; dividends $92.1 million.
- Outlook: Q4 2026 adjusted EPS $1.39 to $1.47; 2026 capex net of grants approximately $260 million to $280 million.

### [Aptar Reports Third Quarter 2026 Results (press release, Exhibit 99.1)](https://www.sec.gov/Archives/edgar/data/896622/000089662226000187/atr-20260930x8kexx991.htm)

Interim report · 2026-10-29

- Q3 2026 results release (October 29, 2026): reported sales +6% to $1.02 billion, core sales +5%, growth in all three segments.
- Reported EPS $0.51 (net income $33 million) after the Russian subsidiary deconsolidation: combined impact $61.2 million before tax, $0.94 per diluted share.
- Adjusted EPS $1.52, at the higher end of guidance, vs $1.62 a year earlier at comparable exchange rates; Adjusted EBITDA margin 21.3% vs 23.2%.
- Pharma core +1%, or 8% adjusting for emergency medicine destocking; margin 36.4%. Beauty core +8%, margin 11.4%. Closures core +11%, margin 15.5%.
- Nine months: sales $3.03 billion (+8%, core +2%); adjusted EPS $4.13 (-10%).
- $61 million returned in Q3, $272 million year to date; quarterly dividend raised from $0.48 to $0.50.
- New CEO Gael Touya: priorities are to "deepen our position with customers, accelerate innovation, execute with greater consistency and allocate capital thoughtfully".
- Q4 2026 adjusted EPS guidance $1.39 to $1.47 (tax rate 17.5% to 19.5%, 1.12 euro to USD).

### [Aptar Q3 2026 earnings call transcript](https://www.mitrade.com/insights/news/live-news/article-8-2220579-20261101)

Executive talk · Gael Touya, President and Chief Executive Officer · 2026-10-30

- Gael Touya's first earnings call as CEO (Q3 2026, October 30, 2026), with CFO Vanessa Kanu.
- Core sales +5% across all three segments; adjusted EBITDA margin 21.3%; Pharma +8% core excluding emergency medicine, which cost about $65 million of sales in 2026 and laps in Q4.
- Priorities: "profitable growth, execution and disciplined capital allocation"; "Sales growth alone is not our objective."
- Pharma pipeline detail: Beat the Blink eye-dosing technology with Bausch + Lomb, nose-to-brain research with Massachusetts General Hospital, Phase III nasal programs in pain and severe allergic reactions, PULMOTREE acquisition (Kolibri liquid inhaler), Premia Precision injectables standard, Stevanato Group collaboration, Mumbai expansion.
- Pharma long-term core growth corridor of 7% to 11% reaffirmed; "around 90% of our business is repeat growing business"; naloxone expected to grow at "GDP, GDP plus" going forward.
- Beauty North America: "I'm not satisfied with the performance of North America"; diagnostic nearly complete; "That's not going to be a quick fix"; Europe and Asia within long-term targets.
- Closures margin diluted 120 basis points by indexation pass-throughs; beverage core +19%.
- Q4 adjusted EPS guide $1.39 to $1.47; capex $260 million to $280 million for 2026; leverage 1.49x; Virginie Maes to become President of Aptar Pharma on January 1.

### [Aptar Q2 2026 earnings call transcript](https://allmind.ai/earnings/event/2934881)

Executive talk · Stephan Tanda, President and Chief Executive Officer · 2026-07-31

- Q2 2026 call (July 31, 2026): Stephan Tanda's final earnings call as CEO; Gaël Touya, CEO from September 1, gave the outlook.
- Reported sales +6% to $1 billion, "a new quarterly record"; core +1%; adjusted EBITDA $213 million, margin 20.7% vs 22.6%; adjusted EPS $1.42, above guidance.
- Emergency medicine sales expected down $65 million in FY2026, two-thirds in H1; Pharma core +8% excluding it; consumer healthcare +15%, injectables +9%.
- Pharma innovation: patent applications for inhaled and nasal GLP-1, N-Sorb nitrosamine solution US patent, injectables collaborative framework; Chiesi's first HFA-152a pMDI approval in the UK using Aptar technology.
- Beauty margin 12.2% (-190 bp); Closures 14.9% (-200 bp) on ramp-ups and maintenance; Middle East conflict raised input costs, largely passed through.
- Tanda on Beauty: Europe "firmly in the target range", Asia above, "We have fallen short in the Americas"; Brazil weak.
- Touya's priorities: deliver the numbers, execution discipline, "extremely thoughtful in our resource allocation"; Pharma 7% to 11% long-term target reaffirmed.
- Q3 adjusted EPS guide $1.45 to $1.53; leverage 1.49; $212 million returned in H1; favorable ruling in the ARS litigation.

## Questions about Aptar

### What does Aptar do?

Aptar designs and manufactures dispensing, dosing and protection technologies such as nasal spray pumps, inhaler valves, injectable components, fragrance pumps and closures for pharma, beauty, food and beverage brands.

### What is Aptar's revenue?

FY2025 net sales were $3.78 billion; Q3 2026 net sales were $1.02 billion, and nine-month 2026 sales were $3.03 billion.

### How many employees does Aptar have?

Approximately 14,000 employees in approximately 20 countries.

### Who leads Aptar?

Gael Touya became President and CEO on September 1, 2026, succeeding Stephan Tanda; Vanessa Kanu is CFO.

### What is Aptar's strategy?

Profitable growth, execution and disciplined capital allocation, led by a Pharma pipeline targeting 7% to 11% long-term core growth and a turnaround of North American Beauty.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
